Standard

(Re)generating Human Beta Cells : Status, Pitfalls, and Perspectives. / Baeyens, Luc; Lemper, Marie; Staels, Willem; De Groef, Sofie; De Leu, Nico; Heremans, Yves; German, Michael S; Heimberg, Harry.

In: Physiological Reviews, Vol. 98, No. 3, 01.07.2018, p. 1143-1167.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Baeyens, Luc ; Lemper, Marie ; Staels, Willem ; De Groef, Sofie ; De Leu, Nico ; Heremans, Yves ; German, Michael S ; Heimberg, Harry. / (Re)generating Human Beta Cells : Status, Pitfalls, and Perspectives. In: Physiological Reviews. 2018 ; Vol. 98, No. 3. pp. 1143-1167.

BibTeX

@article{85a27b40691b4bd4850676c7d5e8abea,
title = "(Re)generating Human Beta Cells: Status, Pitfalls, and Perspectives",
abstract = "Diabetes mellitus results from disturbed glucose homeostasis due to an absolute (type 1) or relative (type 2) deficiency of insulin, a peptide hormone almost exclusively produced by the beta cells of the endocrine pancreas in a tightly regulated manner. Current therapy only delays disease progression through insulin injection and/or oral medications that increase insulin secretion or sensitivity, decrease hepatic glucose production, or promote glucosuria. These drugs have turned diabetes into a chronic disease as they do not solve the underlying beta cell defects or entirely prevent the long-term complications of hyperglycemia. Beta cell replacement through islet transplantation is a more physiological therapeutic alternative but is severely hampered by donor shortage and immune rejection. A curative strategy should combine newer approaches to immunomodulation with beta cell replacement. Success of this approach depends on the development of practical methods for generating beta cells, either in vitro or in situ through beta cell replication or beta cell differentiation. This review provides an overview of human beta cell generation.",
keywords = "Animals, Cell Culture Techniques, Homeostasis, Humans, Insulin-Secreting Cells/physiology, Regeneration",
author = "Luc Baeyens and Marie Lemper and Willem Staels and {De Groef}, Sofie and {De Leu}, Nico and Yves Heremans and German, {Michael S} and Harry Heimberg",
year = "2018",
month = "7",
day = "1",
doi = "10.1152/physrev.00034.2016",
language = "English",
volume = "98",
pages = "1143--1167",
journal = "Physiological Reviews",
issn = "0031-9333",
publisher = "American Physiological Society",
number = "3",

}

RIS

TY - JOUR

T1 - (Re)generating Human Beta Cells

T2 - Status, Pitfalls, and Perspectives

AU - Baeyens, Luc

AU - Lemper, Marie

AU - Staels, Willem

AU - De Groef, Sofie

AU - De Leu, Nico

AU - Heremans, Yves

AU - German, Michael S

AU - Heimberg, Harry

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Diabetes mellitus results from disturbed glucose homeostasis due to an absolute (type 1) or relative (type 2) deficiency of insulin, a peptide hormone almost exclusively produced by the beta cells of the endocrine pancreas in a tightly regulated manner. Current therapy only delays disease progression through insulin injection and/or oral medications that increase insulin secretion or sensitivity, decrease hepatic glucose production, or promote glucosuria. These drugs have turned diabetes into a chronic disease as they do not solve the underlying beta cell defects or entirely prevent the long-term complications of hyperglycemia. Beta cell replacement through islet transplantation is a more physiological therapeutic alternative but is severely hampered by donor shortage and immune rejection. A curative strategy should combine newer approaches to immunomodulation with beta cell replacement. Success of this approach depends on the development of practical methods for generating beta cells, either in vitro or in situ through beta cell replication or beta cell differentiation. This review provides an overview of human beta cell generation.

AB - Diabetes mellitus results from disturbed glucose homeostasis due to an absolute (type 1) or relative (type 2) deficiency of insulin, a peptide hormone almost exclusively produced by the beta cells of the endocrine pancreas in a tightly regulated manner. Current therapy only delays disease progression through insulin injection and/or oral medications that increase insulin secretion or sensitivity, decrease hepatic glucose production, or promote glucosuria. These drugs have turned diabetes into a chronic disease as they do not solve the underlying beta cell defects or entirely prevent the long-term complications of hyperglycemia. Beta cell replacement through islet transplantation is a more physiological therapeutic alternative but is severely hampered by donor shortage and immune rejection. A curative strategy should combine newer approaches to immunomodulation with beta cell replacement. Success of this approach depends on the development of practical methods for generating beta cells, either in vitro or in situ through beta cell replication or beta cell differentiation. This review provides an overview of human beta cell generation.

KW - Animals

KW - Cell Culture Techniques

KW - Homeostasis

KW - Humans

KW - Insulin-Secreting Cells/physiology

KW - Regeneration

UR - http://www.scopus.com/inward/record.url?scp=85046753776&partnerID=8YFLogxK

U2 - 10.1152/physrev.00034.2016

DO - 10.1152/physrev.00034.2016

M3 - Article

C2 - 29717931

VL - 98

SP - 1143

EP - 1167

JO - Physiological Reviews

JF - Physiological Reviews

SN - 0031-9333

IS - 3

ER -

ID: 37595764